Masson et al. [221] evaluated whether circulating miR-132 predicted outcomes in CHF by measuring plasma miR-132 at randomization in 953 GISSI-HF trial participants and relating it to demographics, NT-proBNP, hs-cTnT, hs-CRP, pentraxin-3, and long-term events (all-cause/CV mortality and first CV/HF hospitalization) over 46 months. This evidence concerns the gene TNNT2 and hydrops fetalis.